Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-10-02
2007-10-02
Angell, Jon E. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S178100
Reexamination Certificate
active
10060585
ABSTRACT:
The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.
REFERENCES:
patent: 4997913 (1991-03-01), Hellstrom et al.
patent: 5559099 (1996-09-01), Wickham et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5824782 (1998-10-01), Holzer et al.
patent: 5856140 (1999-01-01), Shimamura et al.
patent: 5876691 (1999-03-01), Chester et al.
patent: 6348584 (2002-02-01), Hodgson et al.
patent: 6514498 (2003-02-01), Antonsson et al.
patent: 6852703 (2005-02-01), Kingsman
patent: 0336562 (1989-10-01), None
patent: 0 803 574 (1990-05-01), None
patent: WO89/07947 (1989-03-01), None
patent: WO92/11383 (1992-07-01), None
patent: WO92/22653 (1992-12-01), None
patent: WO94/11513 (1993-11-01), None
patent: WO96/15238 (1995-11-01), None
patent: WO96/30504 (1996-03-01), None
patent: WO96/30512 (1996-03-01), None
patent: WO96/34969 (1996-05-01), None
patent: WO97/17090 (1997-05-01), None
patent: WO97/36932 (1997-10-01), None
patent: WO98/55607 (1998-12-01), None
patent: PCT/GB00/04317 (2001-05-01), None
patent: WO01/36486 (2001-05-01), None
Greco, O. et al. “Cancer gene therapy: delivery, delivery, delivery.” Frontiers in Bioscience, 2002, vol. 7, pp. d1516-1524.
Crystal, R.G. “Transfer of genes to humans: early lessons and obstacles to success.” Science, 1995, vol. 270, pp. 404-410.
Gertsmayer, B. et al. The Journal of Immunology, vol. 158, pp. 4584-4590 (1997).
Naldini et al (Science, 1996; 272:263-267).
Anderson, W. French, “Human gene therapy,” Nature, vol. 392, Apr. 30, 1998, p. 25-30.
Chamberlain, Ronald S., et al., “Costimulation Enhances the Active Immunotherapy Effect of Recombinant Anticancer Vaccines,” Cancer Research, vol. 56, Jun. 15, 1996, p. 2832-2836.
Forsberg, Goran, et al., Identification of Framework Residues in a Secreted Recombinant Antibody Fragment That Control Production Level and Localization inEscherichia coli, The Journal of Biological Chemistry, vol. 272, No. 19, May 9, 1997, p. 12430-12436.
Mountain, Andrew, “Gene therapy: the first decade,” TIBTECH, vol. 18, Mar. 2000, p. 119-127.
Myers, Kevin A., et al., “Isolation of a cDNA Encoding 5T4 Oncofetal Trophoblast Glycoprotein,” The Journal of Biological Chemistry, vol. 269, No. 12, Mar. 25, 1994, p. 9319-9324.
Verma, Inder M., et al., “Gene therapy promises, problems and prospects,” Nature, VI. 389, Sep. 18, 1997, p. 239-242.
Walther, Wolfgang, et al., “Viral Vectors for Gene Transfer,” Drugs, vol. 2, Aug. 2000, p. 249-271.
Riddell, S.R., et al. “T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients”,Nature Medicine(1996) 2:216-221.
Richter, J., et al. “Clinical gene therapy in hematology: Past and future”,Int. Journal. Hematology(2001) 73:162-169.
Rieger, et al.,Glossary of Genetics and Cytogenetics, Classical and Molecular. 4th Ed., Springer-Verlag, Berlin, 1976.
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity”,Proc. Natl Acad Sci USA(1982) 79:1979-1983.
Overbeek, Paul A., “Factors affecting transgenic animal production”,Transgenic Animal Technology(1994) 96-98.
Wall, R.J. “Transgenic Livestock: Progress and Prospects For The Future”,Theriogenology(1996) 45:57-68.
Houdebine, Louis-Marie, “Production of pharmaceutical proteins from transgenic animals”,J. Biotech(1994) 34:269-287.
Kappel, Catherine A., et al. “Regulating gene expression in transgenic animals”,Current Opinions in Biotechnology(1992) 3:548-553.
Cameron, Ewan R., “Recent Advances in Transgenic Technology”,Molecular Biology(1997) 7:253-265.
Niemann, H. “Transgenic farm animals get off the ground”,Transgenic Research. (1998) 7:73-75.
Mullins, John H., et al. “Transgenesis in Nonmurine Species”,Hypertension(1993) 22:630-633.
Mullins, J.J., et al. “Fulminant hypertension in transgenic rats harbouring the mouseRen-2gene”,Nature(1990) 344:541-544.
Hammer, Robert E., et al. “Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human β2m: An Animal Model of HLA-B27-Associated Human Disorders”,Cell(1990) 63:1099-1112.
Mullins, J.J., et al. “Expression of the DBA/2JRen-2gene in the adrenal gland of transgenic mice”,EMBO Journal(1989) 8(13):4065-4072.
Taurog, Joel D., et al. “HLA-B27 in Inbred and Non-Inbred Transgenic Mice”,Journal of Immunology(1988) 141(11):4020-4023.
Mullins, Linda J., et al. “Transgenesis in the Rat and Larger Mammals”,J. Clin. Invest. (1996) 98:S37-S40.
Chaudhary, et al. “A rapid method of cloning functional variable-region antibody genes inEscherichia colias single-chain Immunotoxins”,PNAS(1990) 87:1066-1070.
Alvarez, R.D., et al. “A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients”,Human Gene Therapy(1997) 8(2):229-242.
Deshane, Jessy et, al. “Targeted tumor killing via an intracellular antibody against erbB-2”,Journal of Clinical Investigation(1995) 96(6):2980-2989.
Wels, W., et al. “Biotechnological and gene therapeutic strategies in cancer treatment”,Gene(1995) 159(1):73-80.
Whittington, H.A., et al. “Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins”,Gene Therapy(1998) 5:770-777.
Jannot, C.B., et al. “Intracellular Expression of a Single-Chain Antibody Directed to the EGFR Leads to Growth Inhibition of Tumor Cells”,Oncogene(1996) 13(2):275-282.
Lamikanra, A., et al. “In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies”,Gene Therapy(2005) 12(12):988-998.
Arafat, W.O., et al. “Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv”,Gene Therapy(2002) 9(4):256-262.
Myers, K. A., et al. “Targeting Immune Effector Molecules to Human Tumor Cells Through Genetic Delivery of 5T4-Specific scFv Fusion Proteins”,Cancer Gene Therapy(2002) 9(11):884-896.
Promega,Catalog of Nucleic Acids(1993/94) p. 215-216.
Bebbington Christopher R.
Carroll Miles W.
Ellard Fiona M.
Kingsman Alan J.
Kingsman Susan M.
Angell Jon E.
Oxford Biomedica (UK) Limited
Townsend and Townsend / and Crew LLP
LandOfFree
Vector system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vector system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vector system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3891873